Sign Up Today and Learn More About TILT Biotherapeutics Stock
Invest in or calculate the value of your shares in TILT Biotherapeutics or other pre-IPO companies through EquityZen's platform.
TILT Biotherapeutics Stock
TILT Biotherapeutics Ltd is the leading company globally working in the area of enabling tumor.
About TILT Biotherapeutics Stock
Founded
2013
Industries
Software, Science and Engineering, Health Care
TILT Biotherapeutics Press Mentions
Stay in the know about the latest news on TILT Biotherapeutics
Key Market Driver In Oncolytic Adenovirus Industry 2025: Surge In Cancer Diagnoses Drives Breakthroughs
einpresswire • Mar 27, 2025
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Market Research 2025: Global Advancements Poised to Transform Oncology Landscape
globenewswire • Mar 04, 2025
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
morningstar • Dec 05, 2024
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
biospace • Dec 05, 2024
TILT Biotherapeutics Provides Update on International Clinical Trial Progress with Intravenous Delivery Regimen for Cancer Immunotherapies
globenewswire • Dec 05, 2024
TILT Biotherapeutics Management
Leadership team at TILT Biotherapeutics
Board Member
Timo Ahopelto
Founder & CEO
Akseli Hemminki
Join now and verify your accreditation status to gain access to:
- TILT Biotherapeutics Current Valuation
- TILT Biotherapeutics Stock Price
- TILT Biotherapeutics Management
- Available deals in TILT Biotherapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- TILT Biotherapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- TILT Biotherapeutics Revenue and Financials
- TILT Biotherapeutics Highlights
- TILT Biotherapeutics Business Model
- TILT Biotherapeutics Risk Factors
- TILT Biotherapeutics Research Report from SACRA Research
Trading TILT Biotherapeutics Stock
How to invest in TILT Biotherapeutics stock?
Accredited investors can buy pre-IPO stock in companies like TILT Biotherapeutics through EquityZen funds. These investments are made available by existing TILT Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell TILT Biotherapeutics stock?
Shareholders can sell their TILT Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."